赖脯胰岛素50联合二甲双胍治疗新诊断超重／肥胖2型糖尿病的疗效分析

目的对新诊断的超重，月巴胖2型糖尿病（T2DM）患者进行赖脯胰岛素50联合二甲双胍的短期强化治疗，评价其疗效和安全性。方法62例新诊断的超重／肥胖T2DM患者按机械抽样法随机分为研究组（32例）和对照组（30例），研究组予以赖脯胰岛素50联合二甲双胍治疗，对照组予以重组人胰岛素及甘精胰岛素治疗，收集疗效及安全性数据进行统计学分析。结果两组治疗后餐前、睡前、凌晨3：00血糖比较差异无统计学意义（P〉0．05）。两组血糖达标时间、低血糖发生率比较差异无统计学意义（P〉0．05）。研究组胰岛素日用量及费用分别为（0．6±0．1）U＆g、（15．8±2．1）元/d，低于对照组的（0．8±0．1）U／kg、（21．3±2．6）元／d，差异有统计学意义（P〈0．05）。结论赖脯胰岛素50联合二甲双胍治疗为新诊断的超重／肥胖T2DM患者提供了一种快速、有效、安全的强化治疗方案，且性价比高。

The therapeutic effect of insulin lispro mix 50/50 combined with mefformin in newly diagnosed overweight/obese type 2 diabetic mellitus patients

Objective To evaluate the therapeutic effect and safety of insulin lispro mix 50/50 combined with mefformin in newly diagnosed overweight/obese type 2 diabetic mellitus patients. Methods Sixty-two patients with newly diagnosed overweight/obsess type 2 diabetic mellitus were randomly divided into observation group （32 cases） and control group （30 cases ） by systematic sampling method. The observation group received insulin lispro mix 50/50 combined with mefforrnin, and the control group received recombinant human insulin and insulin glargine. The therapeutic effect and safety were compared between the 2 groups.Results There were no statistical differences in the blood glucose before eating, before retiring and at mane primo 3：00 between the 2 groups （P 〉 0.05 ）. There were no statistical differences in the time of blood glucose standard and rate of hypoglyeaemia between the 2 groups （P 〉 0.05 ）. Daily insulin dosage and costs in the observation group were lower than those in the control group （0.6 ± 0.1 ） U/kg vs. （0.8 ± 0.1 ） U/kg and （15.8 ± 2.1） yuan/d vs. （21.3 ± 2.6） yuan/d] ,and there were statistical differences （P 〈 0.05）. Conclusion Insulin lispro mix 50/50 combined with mefformin provides a convenient,effective and safe therapy for newly diagnosed overweight/obese type 2 diabetic mellitus patients and high cost performance.